Array Enters Into $150 Million At-The-Market Equity Program
05.14.19
This is only gets display when printing
The Firm represented Jefferies LLC in an SEC-registered at-the-market equity program pursuant to which shares of Array BioPharma Inc.’s (“Array”) (NYSE: ARRY) common stock, having an aggregate sales price of up to $150 million, may be sold from time to time by Jefferies LLC, as sales agent.
Array is a fully integrated, biopharmaceutical company focused on the discovery, development and commercialization of target small molecule drugs to treat patients afflicted with cancer and other high-burden diseases.
The Simpson Thacher team included John C. Ericson, Ashley Yoon and Arielle Trapp (Capital Markets); Vanessa Burrows (Healthcare); Jonathan Cantor and Abigail Hopper (Tax); Elizabeth Gladstone (Intellectual Property); and Nathan Utterback (Executive Compensation and Employee Benefits).